Advertisement

Meeting Coverage

Financial Toxicity in Women with Breast Cancer

Patients with breast cancer prioritized affordability or maintaining functional independence when making treatment decisions. Because of this variability, preference evaluation during treatment decision-making could optimize...

Read More

IO-Only or in Chemo-IO Regimens NSCLC Subgroups

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Read More

The Insider’s Guide to ASCO 2021: Ovarian Cancer

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Read More
Advertisement